In­di­v­ior agrees to pay out $385M to end years­long Sub­ox­one lit­i­ga­tion and ac­cu­sa­tions it pre­vent­ed gener­ic com­pe­ti­tion

Vir­ginia-based In­di­v­ior will pay out $385 mil­lion to bring an end to lit­i­ga­tion over ac­cu­sa­tions it pre­vent­ed gener­ic com­pe­ti­tion to its opi­oid ad­dic­tion treat­ment Sub­ox­one, halt­ing a tri­al sched­uled to be­gin on Oct. 30.

As part of the agree­ment with di­rect pur­chasers who were part of the mul­ti-dis­trict lit­i­ga­tion, In­di­v­ior will pay out the $385 mil­lion in No­vem­ber from its ex­ist­ing cash. The com­pa­ny will al­so take a charge of $228 mil­lion in the third quar­ter and ex­clude that from its ad­just­ed earn­ings.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER